In strain: Iota/B.1.526., L, F, , 
In strain: Epsilon/B.1.429., S, I, , 
In strain: Beta/B.1.351, Gamma/P.1, 19B/501Y., L, F, , 
In strain: Delta/B.1.617.2., T, R, , 
In strain: Gamma/P.1., T, N, , 
In strain: Gamma/P.1., P, S, , 
In strain: Eta/B.1.525., A, V, , 
In strain: Alpha/B.1.1.7, Eta/B.1.525, 19B/501T; May compensate for reduced infectivity of RBD escape mutants., , , , 
In strain: Lambda/C.37., G, V, , 
In strain: Lambda/C.37., T, I, , 
In strain: Beta/B.1.351., D, A, , 
In strain: Iota/B.1.526, B.1.1.318., T, I, , 
In strain: A23.1., R, I, , 
In strain: Gamma/P.1., D, Y, , 
In strain: Kappa/B.1.617.1., G, D, , 
In strain: Alpha/B.1.1.7, Eta/B.1.525, B.1.1.318., , , , 
Frequently in strain Epsilon/B.1.429., W, C, , 
In strain: Kappa/B.1.617.1., E, K, , 
In strain: Delta/B.1.617.2., EFR, G, , 
In strain: A23.1., F, L, , 
In strain: Gamma/P.1., R, S, , 
In strain: Beta/B.1.351., D, G, , 
In strain: 20A.EU1., A, V, , 
In strain: Lambda/C.37., , , , 
In strain: Iota/B.1.526., D, G, , 
In strain: Beta/B.1.351, Gamma/P.1; May enhance affinity to human ACE2 receptor., K, N, , 
In strain: Gamma/P.1., K, T, , 
In strain: Delta/B.1.617.2, Epsilon/B.1.429, Kappa/B.1.617.1, Lambda/C.37, 19B/501Y; Contributes to cellular immunity evasion and increases infectivity., L, R, , 
In strain: B.1.1.298., Y, F, , 
In strain: 20A.EU2, Iota/B.1.526., S, N, , 
In strain: Delta/B.1.617.2., T, K, , 
In strain: Beta/B.1.351, Eta/B.1.525, Theta/P.3, Iota/B.1.526, B.1.1.318, Gamma/P.1, Zeta/P.2; May enhance affinity to human ACE2 receptor., E, K, , 
In strain: Kappa/B.1.617.1., E, Q, , 
In strain: Lambda/C.37., F, S, , 
In strain: 19B/501T., N, T, , 
In strain: Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1, Theta/P.3, 19B/501Y; May enhance affinity to human ACE2 receptor., N, Y, , 
In strain: Alpha/B.1.1.7., A, D, , 
In strain: A23.1., Q, H, , 
In strain Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1, Delta/B.1.617.2, Epsilon/B.1.429, Eta/B.1.525, Theta/P.3, Iota/B.1.526, Kappa/B.1.617.1, Lambda/C.37, B.1.1.318, Zeta/P.2, 20A.EU1, 20A.EU2; common variant; binds to hACE2 more efficiently; produces more infectious particles when cultured in primary human epithelial cells; does not significantly shift SARS-CoV-2 neutralization properties., D, G, , 
In strain: 19B/501Y., A, V, , 
In strain: Gamma/P.1, 19B/501T, 19B/501Y., H, Y, , 
In strain: Eta/B.1.525., Q, H, , 
In strain: Alpha/B.1.1.7, Theta/P.3, B.1.1.318, A23.1., P, H, , 
In strain: Delta/B.1.617.2, Kappa/B.1.617.1., P, R, , 
In strain: Beta/B1.351, Iota/B.1.526., A, V, , 
In strain: Alpha/B.1.1.7., T, I, , 
In strain: B.1.1.318., D, H, , 
In strain: 19B/501Y., D, Y, , 
In strain: Lambda/C.37., T, N, , 
In strain: Eta/B.1.525., F, L, , 
In strain: Delta/B.1.617.2., D, N, , 
In strain: Alpha/B.1.1.7., S, A, , 
In strain: Gamma/P.1., T, I, , 
In strain: Kappa/B.1.617.1., Q, H, , 
In strain: Theta/P.3., E, K, , 
In strain: Theta/P.3., H, Y, , 
In strain: Alpha/B.1.1.7., D, H, , 
In strain: Gamma/P.1, Theta/P.3, Zeta/P.2., V, F, , 
In strain: 19B/501Y., G, V, , 
